Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Syndax Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.

Get SNDX alerts

About Keith A. Goldan

Keith A. Goldan is recorded as CFO at Syndax Pharmaceuticals Inc (SNDX) since June 13, 2022. Syndax Pharmaceuticals Inc reported in an 8-K filed November 2, 2026 that Keith A. Goldan retired as treasurer, effective November 9, 2026. Syndax Pharmaceuticals Inc reported in an 8-K filed November 2, 2026 that Keith A. Goldan retired as principal accounting and financial officer, effective November 9, 2026. Syndax Pharmaceuticals Inc reported in an 8-K filed November 2, 2026 that Keith A. Goldan retired as Chief Financial Officer, effective November 9, 2026. Equibles holds 4 filed executive changes naming Keith A. Goldan; each is listed under recent activity with its source filing. The proxy statement of Syndax Pharmaceuticals Inc reports total compensation of $2,470,802 for Keith A. Goldan in fiscal 2025, including a base salary of $516,900. Disclosed compensation is on record for 4 fiscal years. Syndax Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Syndax Pharmaceuticals Inc includes Michael A. Metzger (CEO and Board Member), Michael Metzger (CEO), Aaron A. Ondrey (CFO and Chief Accounting Officer) and 6 others.

“On November 2, 2026, the Company issued a press release announcing that Keith A. Goldan will retire as the Company’s Chief Financial Officer, principal accounting and financial officer and treasurer effective November 9, 2026, after which he will continue as an advisor for an interim period until his retirement.”
Syndax Pharmaceuticals Inc Form 8-K, filed November 2, 2026 · Read the filing
“On November 2, 2026, the Company issued a press release announcing that Keith A. Goldan will retire as the Company’s Chief Financial Officer, principal accounting and financial officer and treasurer effective November 9, 2026, after which he will continue as an advisor for an interim period until his retirement.”
Syndax Pharmaceuticals Inc Form 8-K, filed November 2, 2026 · Read the filing

Affiliation history

Company network

Leadership on record at Syndax Pharmaceuticals Inc

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Syndax Pharmaceuticals Inc (SNDX) $516,900 $2,470,802
2024 Syndax Pharmaceuticals Inc (SNDX) $497,000 $2,824,133
2023 Syndax Pharmaceuticals Inc (SNDX) $470,300 $2,826,034
2022 Syndax Pharmaceuticals Inc (SNDX) $249,900 $2,992,538

Recent activity